{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T09:27:34Z","timestamp":1793957254588,"version":"4.8.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100016355","name":"Xuzhou Science and Technology Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016355","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012154","name":"Graduate Research and Innovation Projects of Jiangsu Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012154","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jvoice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Voice"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jvoice.2024.12.031","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T22:53:59Z","timestamp":1736895239000},"page":"862-868","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Vonoprazan Fumarate: A Promising Therapeutic Option for the Rapid Relief of Laryngopharyngeal Reflux Disease"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9353-6911","authenticated-orcid":false,"given":"ChaoRong","family":"Bian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YunPeng","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvoice.2024.12.031_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/nyas.14728","article-title":"An update on current treatment strategies for laryngopharyngeal reflux symptoms","volume":"1510","author":"Krause","year":"2022","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jvoice.2024.12.031_bib2","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1177\/0194599819827488","article-title":"Evaluation and management of laryngopharyngeal reflux disease: state of the art review","volume":"160","author":"Lechien","year":"2019","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.jvoice.2024.12.031_bib3","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0892-1997(02)00097-8","article-title":"Validity and reliability of the reflux symptom index (RSI)","volume":"16","author":"Belafsky","year":"2002","journal-title":"J Voice"},{"key":"10.1016\/j.jvoice.2024.12.031_bib4","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1097\/00005537-200108000-00001","article-title":"The validity and reliability of the reflux finding score (RFS)","volume":"111","author":"Belafsky","year":"2001","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jvoice.2024.12.031_bib5","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1177\/0194599820941003","article-title":"Development and validation of the short version of the reflux symptom score: reflux symptom score-12","volume":"164","author":"Lechien","year":"2021","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.jvoice.2024.12.031_bib6","first-page":"1087","article-title":"Analysis of reliability and validity of the Chinese version of reflux symptom score 12","volume":"57","author":"Zheng","year":"2022","journal-title":"Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi"},{"key":"10.1016\/j.jvoice.2024.12.031_bib7","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.3748\/wjg.v28.i28.3608","article-title":"Potassium-competitive acid blockers and gastroesophageal reflux disease","volume":"28","author":"Leowattana","year":"2022","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jvoice.2024.12.031_bib8","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.3748\/wjg.v30.i16.2209","article-title":"Laryngopharyngeal reflux disease: updated examination of mechanisms, pathophysiology, treatment, and association with gastroesophageal reflux disease","volume":"30","author":"Cui","year":"2024","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jvoice.2024.12.031_bib9","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/apt.15641","article-title":"Randomised trial of acid inhibition by vonoprazan 10\/20 mg once daily vs rabeprazole 10\/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH study)","volume":"51","author":"Takeuchi","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jvoice.2024.12.031_bib10","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40262-015-0326-7","article-title":"The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations","volume":"55","author":"Echizen","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jvoice.2024.12.031_bib11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pharmthera.2016.08.001","article-title":"Potassium-competitive acid blockers: advanced therapeutic option for acid-related diseases","volume":"168","author":"Inatomi","year":"2016","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jvoice.2024.12.031_bib12","doi-asserted-by":"crossref","first-page":"1756283","DOI":"10.1177\/1756283X17745776","article-title":"Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date","volume":"11","author":"Sugano","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.jvoice.2024.12.031_bib13","first-page":"66","article-title":"The efficacy of vonoprazan fumarate in the treatment of laryngopharyngeal reflux disease evaluated by the Chinese version of the RSS-12 scale","volume":"39","author":"Bian","year":"2025","journal-title":"J Clin Otorhinolaryngol Head Neck Surg"},{"key":"10.1016\/j.jvoice.2024.12.031_bib14","first-page":"1323","article-title":"Analysis of reliability and validity of the Chinese version of reflux symptom score 12","volume":"57","author":"Han","year":"2022","journal-title":"Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi"},{"key":"10.1016\/j.jvoice.2024.12.031_bib15","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/gutjnl-2019-318365","article-title":"Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis","volume":"69","author":"Xiao","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jvoice.2024.12.031_bib16","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/apt.16959","article-title":"The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double-blind multicentre study","volume":"55","author":"Chen","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jvoice.2024.12.031_bib17","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/s00535-019-01572-y","article-title":"Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease","volume":"54","author":"Miwa","year":"2019","journal-title":"J Gastroenterol"},{"issue":"22","key":"10.1016\/j.jvoice.2024.12.031_bib18","first-page":"S0892-1997","article-title":"There is a good consistency between reflux symptom score-12 and reflux symptom index in Chinese population","volume":"29","author":"Yang","year":"2022","journal-title":"J Voice"},{"key":"10.1016\/j.jvoice.2024.12.031_bib19","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1111\/jgh.16017","article-title":"A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: a systematic review and meta-analysis","volume":"37","author":"Simadibrata","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jvoice.2024.12.031_bib20","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/apt.13331","article-title":"Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis","volume":"42","author":"Ashida","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jvoice.2024.12.031_bib21","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1136\/gutjnl-2015-311304","article-title":"Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study","volume":"65","author":"Murakami","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jvoice.2024.12.031_bib22","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1053\/j.gastro.2022.05.055","article-title":"Vonoprazan triple and dual therapy for helicobacter pylori infection in the United States and Europe: randomized clinical trial","volume":"163","author":"Chey","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jvoice.2024.12.031_bib23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1053\/j.gastro.2022.09.041","article-title":"Vonoprazan versus lansoprazole for healing and maintenance of healing of erosive esophagitis: a randomized trial","volume":"164","author":"Laine","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jvoice.2024.12.031_bib24","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/apt.13461","article-title":"Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis","volume":"43","author":"Ashida","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jvoice.2024.12.031_bib25","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00535-021-01801-3","article-title":"Administration of a standard dose of vonoprazan fumarate delays gastric emptying in Japanese healthy adults: a prospective clinical trial","volume":"56","author":"Ota","year":"2021","journal-title":"J Gastroenterol"}],"container-title":["Journal of Voice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0892199724004685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0892199724004685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:56:37Z","timestamp":1781312197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0892199724004685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0892199724004685"],"URL":"https:\/\/doi.org\/10.1016\/j.jvoice.2024.12.031","relation":{},"ISSN":["0892-1997"],"issn-type":[{"value":"0892-1997","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vonoprazan Fumarate: A Promising Therapeutic Option for the Rapid Relief of Laryngopharyngeal Reflux Disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Voice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvoice.2024.12.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Voice Foundation. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}